Virus-like particle display of HER2 induces potent anti-cancer responses

HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response

(2017) Arianna Palladini et al.   Oncotarget

A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors

(2016) Steven A. Limentani et al.   BREAST CANCER RESEARCH AND TREATMENT

A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer

(2016) Giuseppe Curigliano et al.   BREAST CANCER RESEARCH AND TREATMENT

Immunotherapy in Breast Cancer

(2016) Frederik Marmé   Oncology Research and Treatment

Mannosylation of Virus-Like Particles Enhances Internalization by Antigen Presenting Cells

(2014) Farah Al-Barwani et al.   PLoS One

Cancer Immunotherapy

(2013) J. Couzin-Frankel   SCIENCE

Hypersensitivity to antineoplastic agents: mechanisms and treatment with rapid desensitization

(2012) Mariana Castells et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Molecular mechanisms of T-cell tolerance

(2011) Roza I. Nurieva et al.   IMMUNOLOGICAL REVIEWS

The Human Splice Variant Δ16HER2 Induces Rapid Tumor Onset in a Reporter Transgenic Mouse

(2011) Cristina Marchini et al.   PLoS One